

David W Cescon

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2912210/david-w-cescon-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

82
papers

5,344
citations

32
h-index

73
g-index

98
ext. papers

7,036
ext. citations

9.1
avg, IF

5.29
L-index

#	Paper	IF	Citations
82	Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. <i>JAMA - Journal of the American Medical Association</i> , 2003 , 289, 2801-9	27.4	960
81	Functional variants of OCTN cation transporter genes are associated with Crohn disease. <i>Nature Genetics</i> , 2004 , 36, 471-5	36.3	661
80	Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. <i>Cancer Cell</i> , 2015 , 27, 211-22	24.3	548
79	Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. <i>Annals of Oncology</i> , 2019 , 30, 397-404	10.3	313
78	Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. <i>Lancet, The</i> , 2020 , 396, 1817-1828	40	306
77	Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. <i>Annals of Oncology</i> , 2019 , 30, 405-411	10.3	246
76	BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. <i>Journal of Experimental Medicine</i> , 2013 , 210, 1529-44	16.6	197
75	Circulating tumor DNA and liquid biopsy in oncology.. <i>Nature Cancer</i> , 2020 , 1, 276-290	15.4	123
74	Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2. <i>Cancer Cell</i> , 2016 , 30, 337-348	24.3	121
73	Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent. <i>Cancer Cell</i> , 2014 , 26, 163-76	24.3	121
72	Evolution of the randomized controlled trial in oncology over three decades. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5458-64	2.2	105
71	APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 2841-6	11.5	95
70	Mule/Huwe1/Arf-BP1 suppresses Ras-driven tumorigenesis by preventing c-Myc/Miz1-mediated down-regulation of p21 and p15. <i>Genes and Development</i> , 2013 , 27, 1101-14	12.6	93
69	Estrogen controls the survival of BRCA1-deficient cells via a PI3K-NRF2-regulated pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 4472-7	11.5	86
68	Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 4326-4335	11.5	78
67	Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2018 , 110,	9.7	76
66	If we build it they will come: targeting the immune response to breast cancer. <i>Npj Breast Cancer</i> , 2019 , 5, 37	7.8	76

65	Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086. <i>Annals of Oncology</i> , 2017 , 28, v608	10.3	76
64	Targeting the cell cycle in breast cancer: towards the next phase. <i>Cell Cycle</i> , 2018 , 17, 1871-1885	4.7	60
63	Invasive pulmonary aspergillosis associated with marijuana use in a man with colorectal cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2214-5	2.2	58
62	Noncoding somatic and inherited single-nucleotide variants converge to promote ESR1 expression in breast cancer. <i>Nature Genetics</i> , 2016 , 48, 1260-6	36.3	53
61	MYC Interacts with the G9a Histone Methyltransferase to Drive Transcriptional Repression and Tumorigenesis. <i>Cancer Cell</i> , 2018 , 34, 579-595.e8	24.3	52
60	Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, 1913-1918	11.5	48
59	AhR controls redox homeostasis and shapes the tumor microenvironment in BRCA1-associated breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 3604-3613	11.5	45
58	GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer. <i>Nature Communications</i> , 2020 , 11, 4205	17.4	41
57	Extended adjuvant tamoxifen for early breast cancer: a meta-analysis. <i>PLoS ONE</i> , 2014 , 9, e88238	3.7	40
56	Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials. <i>European Journal of Cancer</i> , 2017 , 77, 40-47	7.5	39
55	A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy. <i>Breast</i> , 2019 , 48, 17-23	3.6	38
54	NRF2 Pathway Activation and Adjuvant Chemotherapy Benefit in Lung Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2015 , 21, 2499-505	12.9	35
53	Epigenetic Switch-Induced Viral Mimicry Evasion in Chemotherapy-Resistant Breast Cancer. <i>Cancer Discovery</i> , 2020 , 10, 1312-1329	24.4	34
52	p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis. <i>Clinical Cancer Research</i> , 2009 , 15, 3103-9	12.9	34
51	Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E1570-E1577	11.5	32
50	Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer. <i>Npj Breast Cancer</i> , 2019 , 5, 34	7.8	32
49	Pharmacogenetic and germline prognostic markers of lung cancer. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 296-304	8.9	31
48	Benchmarking to the Gold Standard: Hyaluronan-Oxime Hydrogels Recapitulate Xenograft Models with In Vitro Breast Cancer Spheroid Culture. <i>Advanced Materials</i> , 2019 , 31, e1901166	24	29

47	Presentation of nonfinal results of randomized controlled trials at major oncology meetings. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3938-44	2.2	24
46	Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer. <i>Annals of Oncology</i> , 2010 , 21, 1411-1418	10.3	23
45	W4R variant in CSRP3 encoding muscle LIM protein in a patient with hypertrophic cardiomyopathy. <i>Molecular Genetics and Metabolism</i> , 2005 , 84, 374-5	3.7	20
44	Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018 , 168, 159-168	4.4	19
43	Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts. <i>Cancer Research</i> , 2019 , 79, 4539-4550	4.5	18
42	Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial. <i>British Journal of Cancer</i> , 2019 , 121, 318-324	8.7	18
41	Barcoded medication administration: a last line of defense. <i>JAMA - Journal of the American Medical Association</i> , 2008 , 299, 2200-2	27.4	16
40	Feasibility of a randomized controlled trial of vitamin D vs. placebo in women with recently diagnosed breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012 , 134, 759-67	4.4	15
39	CD2BP1 and CARD15 mutations are not associated with pyoderma gangrenosum in patients with inflammatory bowel disease. <i>Journal of Investigative Dermatology</i> , 2004 , 122, 1054-6	4.3	14
38	DNA replication stress: a source of APOBEC3B expression in breast cancer. <i>Genome Biology</i> , 2016 , 17, 202	18.3	14
37	A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI9041). <i>Investigational New Drugs</i> , 2016 , 34, 104-11	4.3	13
36	Discoloration of skin and urine after treatment with hydroxocobalamin for cyanide poisoning. <i>Cmaj</i> , 2009 , 180, 251	3.5	12
35	Association of MDM2 T309G and p53 Arg72Pro polymorphisms and gastroesophageal reflux disease with survival in esophageal adenocarcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013 , 28, 1482-8	4	11
34	Breaking up is hard to do: PI3K isoforms on the rebound. <i>Cancer Cell</i> , 2015 , 27, 5-7	24.3	10
33	MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with Tc(I) Tricarbonyl Complex. <i>Molecular Pharmaceutics</i> , 2019 , 16, 3559-3568	5.6	9
32	Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2018 , 169, 413-425	4.4	9
31	Pharmacology and in vivo efficacy of pyridine-pyrimidine amides that inhibit microtubule polymerization. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018 , 28, 934-941	2.9	9
30	Mevalonate Pathway Inhibition Slows Breast Cancer Metastasis via Reduced -glycosylation Abundance and Branching. <i>Cancer Research</i> , 2021 , 81, 2625-2635	10.1	9

29	LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC. <i>Annals of Oncology</i> , 2021 , 32, S1289-S1290	10.3	8
28	Tyrosine Threonine Kinase Inhibition Eliminates Lung Cancers by Augmenting Apoptosis and Polyploidy. <i>Molecular Cancer Therapeutics</i> , 2019 , 18, 1775-1786	6.1	7
27	BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial. <i>Clinical Cancer Research</i> , 2017 , 23, 2460-2470	12.9	7
26	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. <i>JNCI Cancer Spectrum</i> , 2019 , 3, pkz050	4.6	6
25	Evolution in sites of recurrence over time in breast cancer patients treated with adjuvant endocrine therapy. <i>Cancer Treatment Reviews</i> , 2018 , 70, 138-143	14.4	6
24	Anticancer effects of radiation therapy combined with Polo-Like Kinase 4 (PLK4) inhibitor CFI-400945 in triple negative breast cancer. <i>Breast</i> , 2021 , 58, 6-9	3.6	6
23	Biomimetic hydrogel supports initiation and growth of patient-derived breast tumor organoids.. <i>Nature Communications</i> , 2022 , 13, 1466	17.4	6
22	Abstract CT066: First-in-human phase I trial of the oral PLK4 inhibitor CFI-400945 in patients with advanced solid tumors 2016 ,		5
21	Microfluidic Arrays of Breast Tumor Spheroids for Drug Screening and Personalized Cancer Therapies. <i>Advanced Healthcare Materials</i> , 2021 , e2101085	10.1	5
20	Association between BMI, vitamin D, and estrogen levels in postmenopausal women using adjuvant letrozole: a prospective study. <i>Npj Breast Cancer</i> , 2020 , 6, 22	7.8	4
19	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. <i>JNCI Cancer Spectrum</i> , 2019 , 3, pkz049	4.6	4
18	The Antiarrhythmic Drug, Dronedarone, Demonstrates Cytotoxic Effects in Breast Cancer Independent of Thyroid Hormone Receptor Alpha 1 (THR1) Antagonism. <i>Scientific Reports</i> , 2018 , 8, 16562	4.9	4
17	Biomarkers of outcome to weekly paclitaxel in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2020 , 159, 539-545	4.9	3
16	Reply to Oegema et al.: CFI-400945 and Polo-like kinase 4 inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E10810-E10811	11.5	3
15	PRMT inhibition induces a viral mimicry response in triple-negative breast cancer.. <i>Nature Chemical Biology</i> , 2022 ,	11.7	3
14	430 Phase III KEYNOTE-355 study of pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC): Results for patients (Pts) enrolled in Asia. <i>Annals of Oncology</i> , 2020 , 31, S1257	10.3	2
13	Assessing therapy response in patient-derived xenografts. <i>Science Translational Medicine</i> , 2021 , 13, eabf4969	14.9	2
12	Novel classes of immunotherapy for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021 , 1	4.4	2

11	Transcriptomic Determinants of Response to Pembrolizumab Monotherapy Across Solid Tumor Types.. <i>Clinical Cancer Research</i> , 2021 ,	12.9	2
10	Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches.. <i>Frontiers in Oncology</i> , 2021 , 11, 667397	5.3	1
9	Breast cancer immune microenvironment: from pre-clinical models to clinical therapies. <i>Breast Cancer Research and Treatment</i> , 2021 , 1	4.4	1
8	Pembrolizumab monotherapy in metastatic triple-negative breast cancer. <i>Lancet Oncology</i> , 2021 , 22, 415-417	21.7	1
7	No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer.. <i>British Journal of Cancer</i> , 2021 ,	8.7	1
6	Patterns of Recurrence and Predictors of Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy, Surgery, and Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020 , 108, 676-685	4	0
5	Radiotherapy and Radiosensitization in Breast Cancer: Molecular Targets and Clinical Applications. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 169, 103566	7	0
4	Network Meta-analysis Comparing Efficacy, Safety and Tolerability of Anti-PD-1/PD-L1 Antibodies in Solid Cancers. <i>Journal of Cancer</i> , 2021 , 12, 4372-4378	4.5	0
3	Phase I trial of trebananib (AMG 386) plus temsirolimus (Tr + T) in patients (pts) with advanced solid tumors (PJC-008/NCI#9041).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2534-2534	2.2	
2	Prognostic and predictive effects of a gene expression signature for NRF2 pathway activation in lung squamous cell carcinoma (SqCC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 7517-7517	2.2	
1	Accelerating drug access from advanced to early breast cancer: the special case of oral selective estrogen receptor degraders. <i>Current Opinion in Oncology</i> , 2021 , 33, 538-546	4.2	